RU2009105491A - Сероводородные производные нестероидных противовоспалительных лекарственных средств - Google Patents
Сероводородные производные нестероидных противовоспалительных лекарственных средств Download PDFInfo
- Publication number
- RU2009105491A RU2009105491A RU2009105491/04A RU2009105491A RU2009105491A RU 2009105491 A RU2009105491 A RU 2009105491A RU 2009105491/04 A RU2009105491/04 A RU 2009105491/04A RU 2009105491 A RU2009105491 A RU 2009105491A RU 2009105491 A RU2009105491 A RU 2009105491A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- furobofenophen
- compound according
- acid
- nsaid
- Prior art date
Links
- YCNMAPLPQYQJFC-UHFFFAOYSA-N CC(C(Oc(cc1)ccc1C(N)=S)=O)c1ccc(cc(cc2)OC)c2c1 Chemical compound CC(C(Oc(cc1)ccc1C(N)=S)=O)c1ccc(cc(cc2)OC)c2c1 YCNMAPLPQYQJFC-UHFFFAOYSA-N 0.000 description 1
- ABPAEYXKEGBGCR-UHFFFAOYSA-N CC(C(Oc(cc1)ccc1C(SS1)=CC1=S)=O)c(ccc1c2)cc1ccc2OC Chemical compound CC(C(Oc(cc1)ccc1C(SS1)=CC1=S)=O)c(ccc1c2)cc1ccc2OC ABPAEYXKEGBGCR-UHFFFAOYSA-N 0.000 description 1
- XEBPXKSWLFKJPA-UHFFFAOYSA-N CC(Oc(cccc1)c1C(Oc(cc1)ccc1C(SS1)=CC1=S)=O)=O Chemical compound CC(Oc(cccc1)c1C(Oc(cc1)ccc1C(SS1)=CC1=S)=O)=O XEBPXKSWLFKJPA-UHFFFAOYSA-N 0.000 description 1
- SJLZXDOBSHEDIF-UHFFFAOYSA-N Cc1c(CC(Oc(cc2)ccc2C(SS2)=CC2=S)=O)c(cc(cc2)OC)c2[n]1C(c(cc1)ccc1Cl)=O Chemical compound Cc1c(CC(Oc(cc2)ccc2C(SS2)=CC2=S)=O)c(cc(cc2)OC)c2[n]1C(c(cc1)ccc1Cl)=O SJLZXDOBSHEDIF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединение или его соль общей формулы ! ! где А представляет собой NSAID радикал, Y выбирают из группы, состоящей из -C(O)O-, -C(O)NH-, -C(O)OC(O)-, -C(O)NHCH2C(O)- или нуля, и Х представляет собой фрагмент, способный высвобождать сероводород, или сам по себе, или при связывании с NSAID, таким образом, что, если Y представляет собой нуль, соединение может представлять собой соль А и Х. ! 2. Соединение общей формулы ! ! где В-C(O)O- представляет собой производное NSAID, имеющего свободную карбоксильную группу, или карбокси-замещенного NSAID, и X выбирают из группы, состоящей из ! , ! , ! , ! ! и ! . ! 3. Соединение по п.1 или 2, где NSAID выбирают из группы, состоящей из ацетилсалициловой кислоты (ASA), диклофенака, напроксена, индометацина, флурбипрофена, сулиндака, ибупрофена, ацеклофенака, ацеметацина, беноксапрофена, бензофенака, бромфенака, буклоксовой кислоты, бутибуфена, карпрофена, целекоксиба, циклопрофена, цинметацина, клиденака, клопирака, дифлузинала, этодолака, эторикоксиба, фенбуфена, фенклофенака, фенклорака, фенопрофена, фентиазака, флуноксапрофена, фурапрофена, фуробуфена, фурафенака, ибуфенака, индопрофена, изоксепака, кетопрофена, кеторолака, локсопрофена, лоназолака, люмиракоксиба, метиазиника, мефенамовой кислоты, меклофенамовой кислоты, мелоксикама, набуметона, пиромидовой кислоты, салсалата, миропрофена, оксапрозина, оксепинака, паракоксиба, фенилбутазона, пирпрофена, пироксикама, пирозолака, протизиновой кислоты, рофекоксиба, салицилата натрия, супрофена, тиапрофеновой кислоты, толметина, вальдекоксиба и зомепирака. ! 4. Соединение по п.1 или 2, где NSAID выбирают из группы, состоящей из ацетилсалициловой кислоты, диклофенака, индомета�
Claims (25)
1. Соединение или его соль общей формулы
где А представляет собой NSAID радикал, Y выбирают из группы, состоящей из -C(O)O-, -C(O)NH-, -C(O)OC(O)-, -C(O)NHCH2C(O)- или нуля, и Х представляет собой фрагмент, способный высвобождать сероводород, или сам по себе, или при связывании с NSAID, таким образом, что, если Y представляет собой нуль, соединение может представлять собой соль А и Х.
3. Соединение по п.1 или 2, где NSAID выбирают из группы, состоящей из ацетилсалициловой кислоты (ASA), диклофенака, напроксена, индометацина, флурбипрофена, сулиндака, ибупрофена, ацеклофенака, ацеметацина, беноксапрофена, бензофенака, бромфенака, буклоксовой кислоты, бутибуфена, карпрофена, целекоксиба, циклопрофена, цинметацина, клиденака, клопирака, дифлузинала, этодолака, эторикоксиба, фенбуфена, фенклофенака, фенклорака, фенопрофена, фентиазака, флуноксапрофена, фурапрофена, фуробуфена, фурафенака, ибуфенака, индопрофена, изоксепака, кетопрофена, кеторолака, локсопрофена, лоназолака, люмиракоксиба, метиазиника, мефенамовой кислоты, меклофенамовой кислоты, мелоксикама, набуметона, пиромидовой кислоты, салсалата, миропрофена, оксапрозина, оксепинака, паракоксиба, фенилбутазона, пирпрофена, пироксикама, пирозолака, протизиновой кислоты, рофекоксиба, салицилата натрия, супрофена, тиапрофеновой кислоты, толметина, вальдекоксиба и зомепирака.
4. Соединение по п.1 или 2, где NSAID выбирают из группы, состоящей из ацетилсалициловой кислоты, диклофенака, индометацина, люмиракоксиба, напроксена, ибупрофена, кетопрофена и флурбипрофена.
22. Фармацевтическая композиция, содержащая соединение по любому из пп.1-21 и фармацевтически приемлемый эксципиент или носитель.
23. Применение соединения по любому из пп.1-21 для лечения воспаления у пациента, нуждающегося в таком лечении, включающее введение пациенту облегчающего воспаление количества соединения.
24. Применение соединения по любому из пп.1-21 для лечения боли у пациента, нуждающегося в таком лечении, включающее введение пациенту облегчающего воспаление количества соединения.
25. Применение соединения по любому из пп.1-21 для лечения лихорадочного состояния у пациента, нуждающегося в таком лечении, включающее введение пациенту облегчающего воспаление количества соединения.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80763906P | 2006-07-18 | 2006-07-18 | |
US60/807,639 | 2006-07-18 | ||
US88718807P | 2007-01-30 | 2007-01-30 | |
US60/887,188 | 2007-01-30 | ||
PCT/CA2007/001289 WO2008009127A1 (en) | 2006-07-18 | 2007-07-18 | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009105491A true RU2009105491A (ru) | 2010-08-27 |
RU2468019C2 RU2468019C2 (ru) | 2012-11-27 |
Family
ID=38956479
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009105491/04A RU2468019C2 (ru) | 2006-07-18 | 2007-07-18 | Сероводородные производные нестероидных противовоспалительных лекарственных средств |
RU2009105498/04A RU2465271C2 (ru) | 2006-07-18 | 2007-07-18 | 4-гидрокситиобензамидные производные лекарственных веществ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009105498/04A RU2465271C2 (ru) | 2006-07-18 | 2007-07-18 | 4-гидрокситиобензамидные производные лекарственных веществ |
Country Status (18)
Country | Link |
---|---|
US (1) | US8314140B2 (ru) |
EP (2) | EP2041108B1 (ru) |
JP (2) | JP5529534B2 (ru) |
KR (2) | KR101450653B1 (ru) |
AU (2) | AU2007276679B2 (ru) |
BR (2) | BRPI0714330A2 (ru) |
CA (2) | CA2658429A1 (ru) |
DK (1) | DK2057139T3 (ru) |
ES (1) | ES2437223T3 (ru) |
HK (2) | HK1131125A1 (ru) |
IL (2) | IL196228A0 (ru) |
MX (2) | MX2009000750A (ru) |
NO (2) | NO20090764L (ru) |
NZ (1) | NZ573996A (ru) |
PL (1) | PL2057139T3 (ru) |
PT (1) | PT2057139E (ru) |
RU (2) | RU2468019C2 (ru) |
WO (2) | WO2008009118A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2465271C2 (ru) * | 2006-07-18 | 2012-10-27 | Антиб Терапьютикс Инк. | 4-гидрокситиобензамидные производные лекарственных веществ |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
ITMI20080382A1 (it) * | 2008-03-07 | 2009-09-08 | Ctg Pharma S R L | Composizioni farmaceutiche oculari |
ITMI20081167A1 (it) * | 2008-06-26 | 2009-12-27 | Ctg Pharma S R L | Composizioni farmaceutiche per il trattamento di malattie neurodegenerative |
US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
WO2011053597A1 (en) * | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
US9242009B2 (en) | 2012-07-17 | 2016-01-26 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
CN109414596B (zh) | 2016-05-12 | 2023-09-29 | 密歇根大学董事会 | Ash1l抑制剂和用其进行治疗的方法 |
EP3706737A4 (en) * | 2017-11-10 | 2021-10-20 | The Regents of the University of Michigan | ASH11 INHIBITORS AND METHOD OF TREATING THEREOF |
JP2021066660A (ja) * | 2018-02-09 | 2021-04-30 | アピオン・ジャパン有限会社 | Tirap阻害剤 |
WO2022115952A1 (en) * | 2020-12-03 | 2022-06-09 | Antibe Therapeutics Inc. | [1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-acetic acid 4-thiocarbamoyl-phenyl ester for the treatment of a viral infection |
WO2023159296A1 (en) * | 2022-02-28 | 2023-08-31 | Antibe Therapeutics Inc. | 4-thiocarbamoylphenyl 2-(4-oxophenyl)-phenyl propanoate for the treatment of pain associated with urologic chronic pelvic pain syndrome |
GR1010438B (el) * | 2022-03-21 | 2023-04-06 | UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", | Φαρμακευτικες ενωσεις που βασιζονται στο συνδυασμο ενος ανταγωνιστη της ισταμινης και ενος δοτη υδροθειου για χρηση στην αντιμετωπιση του κνησμου |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE628299A (ru) | 1961-01-05 | |||
US4170654A (en) | 1976-02-13 | 1979-10-09 | Merck & Co., Inc. | Antihypertensive compositions containing N-heterocyclicalanines and α- |
US4112095A (en) | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
US5663416A (en) | 1990-05-22 | 1997-09-02 | Cortech Inc. | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase |
US5214191A (en) | 1990-05-22 | 1993-05-25 | Cortech, Inc. | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase |
EP0937711A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1314184B1 (it) * | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
US6429223B1 (en) | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US7638513B2 (en) | 2004-06-02 | 2009-12-29 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
EP1630164A1 (en) * | 2004-08-31 | 2006-03-01 | Expotrend Company SA | Pyrazolopyrimidinones as phosphodiesterase inhibitors |
EP1645288A1 (en) * | 2004-10-07 | 2006-04-12 | CTG Pharma S.r.l. | New nuclear transcription factors regulators |
CN2757375Y (zh) * | 2004-11-25 | 2006-02-08 | 富士康(昆山)电脑接插件有限公司 | 电子卡连接器 |
EP1836160A1 (en) * | 2004-12-24 | 2007-09-26 | CTG Pharma S.r.l. | Compounds for treating metabolic syndrome |
WO2006100254A1 (en) | 2005-03-24 | 2006-09-28 | Nycomed Gmbh | 6-thioamide substituted benzimidazoles |
ITMI20050680A1 (it) * | 2005-04-18 | 2006-10-19 | Ctg Pharma S R L | Nuovi composti anti-infiammatori |
US7498355B2 (en) | 2005-05-27 | 2009-03-03 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
WO2006125293A1 (en) * | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
US20060270635A1 (en) * | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
NZ573996A (en) * | 2006-07-18 | 2012-03-30 | Antibe Therapeutics Inc | 4-Thiocarbamoyl-phenyl esters of statin derivatives |
-
2007
- 2007-07-18 NZ NZ573996A patent/NZ573996A/en not_active IP Right Cessation
- 2007-07-18 RU RU2009105491/04A patent/RU2468019C2/ru active
- 2007-07-18 MX MX2009000750A patent/MX2009000750A/es active IP Right Grant
- 2007-07-18 US US12/374,273 patent/US8314140B2/en not_active Expired - Fee Related
- 2007-07-18 AU AU2007276679A patent/AU2007276679B2/en not_active Ceased
- 2007-07-18 PL PL07763931T patent/PL2057139T3/pl unknown
- 2007-07-18 CA CA002658429A patent/CA2658429A1/en not_active Abandoned
- 2007-07-18 JP JP2009519765A patent/JP5529534B2/ja not_active Expired - Fee Related
- 2007-07-18 JP JP2009519769A patent/JP5408719B2/ja active Active
- 2007-07-18 KR KR1020097001029A patent/KR101450653B1/ko active IP Right Grant
- 2007-07-18 MX MX2009000749A patent/MX2009000749A/es active IP Right Grant
- 2007-07-18 DK DK07763931.8T patent/DK2057139T3/da active
- 2007-07-18 CA CA2658433A patent/CA2658433C/en active Active
- 2007-07-18 RU RU2009105498/04A patent/RU2465271C2/ru not_active IP Right Cessation
- 2007-07-18 ES ES07763931.8T patent/ES2437223T3/es active Active
- 2007-07-18 BR BRPI0714330-3A patent/BRPI0714330A2/pt not_active IP Right Cessation
- 2007-07-18 WO PCT/CA2007/001273 patent/WO2008009118A1/en active Application Filing
- 2007-07-18 WO PCT/CA2007/001289 patent/WO2008009127A1/en active Application Filing
- 2007-07-18 PT PT77639318T patent/PT2057139E/pt unknown
- 2007-07-18 EP EP07763921.9A patent/EP2041108B1/en not_active Not-in-force
- 2007-07-18 KR KR1020097001128A patent/KR101495520B1/ko not_active IP Right Cessation
- 2007-07-18 BR BRPI0714466A patent/BRPI0714466B8/pt active IP Right Grant
- 2007-07-18 AU AU2007276621A patent/AU2007276621B2/en active Active
- 2007-07-18 EP EP07763931.8A patent/EP2057139B1/en active Active
-
2008
- 2008-12-28 IL IL196228A patent/IL196228A0/en unknown
- 2008-12-28 IL IL196229A patent/IL196229A/en active IP Right Grant
-
2009
- 2009-02-17 NO NO20090764A patent/NO20090764L/no not_active Application Discontinuation
- 2009-02-17 NO NO20090763A patent/NO342083B1/no unknown
- 2009-09-30 HK HK09109069.8A patent/HK1131125A1/xx not_active IP Right Cessation
- 2009-10-28 HK HK09109992.0A patent/HK1131973A1/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2465271C2 (ru) * | 2006-07-18 | 2012-10-27 | Антиб Терапьютикс Инк. | 4-гидрокситиобензамидные производные лекарственных веществ |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009105491A (ru) | Сероводородные производные нестероидных противовоспалительных лекарственных средств | |
US20100210607A1 (en) | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs | |
Brzozowski et al. | Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins | |
NZ601529A (en) | Tapentadol compositions | |
JP2009543813A5 (ru) | ||
Kourounakis et al. | Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs | |
Fiorucci et al. | Hydrogen sulfide-based therapies: focus on H2S releasing NSAIDs | |
CO5070601A1 (es) | Suspencion peroral de meloxicam micronizado que cuenta con bajas proporciones de dioxido de silicio y un polimero hidrofilico como hidroxietilcelulosa, en un medio de dispercion constituido por una solucion reguladora en un rango de ph de 2 a 4 | |
CN101501018B (zh) | 非甾体抗炎药的硫化氢衍生物 | |
RU2018140051A (ru) | Производные нестероидных противовоспалительных средств | |
WO2004000300A1 (en) | Cyclooxygenase-2 inhibitors | |
RU2016148183A (ru) | (s)-пирлиндол и его фармацевтические приемлемые соли для применения в медицине | |
RU2016148182A (ru) | (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине | |
ES2270634T3 (es) | Conversion de compuestos de inhibicion de cox que no son inhibidores selectivos de cox-2 en derivados que son inhibidores selectivos de cox-2. | |
BRPI0800951A2 (pt) | novos compostos derivados de taurina e seus usos, processo de sua preparação e composições farmacêuticas contendo os mesmos | |
Wallace et al. | New generation NSAIDS: The benefits without the risks? | |
Kulabaş et al. | Identification of some novel amide conjugates as potent and gastric sparing anti-inflammatory agents: In vitro, in vivo, in silico studies and drug safety evaluation | |
AR063228A1 (es) | Antinflamatorios no esteroideos contra la tos | |
WO2005030224A1 (en) | Nitrosylated analgesic and/or anti-inflammatory drugs having antiviral activity | |
JP2002534361A5 (ru) | ||
Ellis et al. | NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor | |
EA201401270A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ (1R,4R)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'H-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН И НПРС | |
ES2280589T3 (es) | Uso de derivados de acido 4-oxobutanoico en el tratamiento de la inflamacion. | |
Goyal et al. | Insights into Prospects of Novel NSAID Prodrugs in the Management of Gastrointestinal Toxicity: A Perspective Review | |
Krishna et al. | Synthesis, characterization and pharmacological screening of etodolac amino acid’s mutual prodrugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner |